ATE122237T1 - Hiv-1 neutralisierende monoklonale antikörper. - Google Patents
Hiv-1 neutralisierende monoklonale antikörper.Info
- Publication number
- ATE122237T1 ATE122237T1 AT88906589T AT88906589T ATE122237T1 AT E122237 T1 ATE122237 T1 AT E122237T1 AT 88906589 T AT88906589 T AT 88906589T AT 88906589 T AT88906589 T AT 88906589T AT E122237 T1 ATE122237 T1 AT E122237T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv
- antibodies
- monoclonal antibodies
- neutralizing monoclonal
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5744587A | 1987-05-29 | 1987-05-29 | |
| US13786187A | 1987-12-24 | 1987-12-24 | |
| US19776688A | 1988-05-23 | 1988-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE122237T1 true ATE122237T1 (de) | 1995-05-15 |
Family
ID=27369250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT88906589T ATE122237T1 (de) | 1987-05-29 | 1988-05-27 | Hiv-1 neutralisierende monoklonale antikörper. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0366718B1 (de) |
| JP (1) | JP2520464B2 (de) |
| AT (1) | ATE122237T1 (de) |
| CA (1) | CA1339857C (de) |
| DE (1) | DE3853779T2 (de) |
| WO (1) | WO1988009181A2 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591829A (en) * | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
| US5854400A (en) * | 1987-05-29 | 1998-12-29 | Tanox, Inc. | Monoclonal antibodies which neutralize HIV-1 infection |
| US5834599A (en) * | 1987-05-29 | 1998-11-10 | Tanox Biosystems, Inc. | Immunoconjugates which neutralize HIV-1 infection |
| WO1989007112A1 (en) * | 1988-01-26 | 1989-08-10 | The United States Of America, As Represented By Th | A synthetic antigen evoking anti-hiv response |
| JP2646007B2 (ja) * | 1988-01-30 | 1997-08-25 | 財団法人 化学及血清療法研究所 | 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法 |
| US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
| CA1341285C (en) * | 1988-02-12 | 2001-08-14 | Chang Yi Wang | Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines |
| US5562905A (en) * | 1988-04-26 | 1996-10-08 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
| EP0339504A3 (de) * | 1988-04-26 | 1990-09-12 | The Du Pont Merck Pharmaceutical Company | Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen |
| JPH02504284A (ja) * | 1988-05-13 | 1990-12-06 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 抗原、および、抗イディオタイプ抗体、または抗原に対する細胞受容体に特異的な抗体に共通のアミノ酸配列に由来する免疫原および生物学的活性ペプチド |
| EP0436634A1 (de) * | 1988-10-03 | 1991-07-17 | Repligen Corporation | Hiv-proteine und peptide und deren verwendung zur diagnose, prophylaxe und therapie von aids |
| EP0365209A3 (de) * | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Aminosäuresequenz des Anti-leu 3a |
| IL89491A0 (en) * | 1988-11-17 | 1989-09-10 | Hybritech Inc | Bifunctional chimeric antibodies |
| CA2051107A1 (en) * | 1989-04-25 | 1990-10-26 | William N. Sun | Antibodies specific for cd4-binding domain of hiv |
| JP2782232B2 (ja) * | 1989-05-29 | 1998-07-30 | 日東電工株式会社 | プロテアーゼ阻害剤 |
| PT94276A (pt) * | 1989-06-05 | 1991-02-08 | Anticorpo monoclonal capaz de neutralizar o prototipo mn de hiv | |
| CA2022959C (en) * | 1989-08-10 | 2001-03-20 | Hiroaki Maeda | Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin |
| US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
| CA1339415C (en) * | 1989-08-24 | 1997-09-02 | Milton David Goldenberg | Detection and treatment of infections with immunoconjugates |
| AU6953091A (en) * | 1989-11-13 | 1991-06-13 | Xoma Corporation | Chimeric mouse human antibodies with specificity to hiv antigens |
| WO1991007493A1 (en) * | 1989-11-13 | 1991-05-30 | Xoma Corporation | Chimeric mouse human antibodies with specificity to hiv antigens |
| DE69028713T3 (de) * | 1989-12-27 | 2004-05-13 | Centocor, Inc. | Schimäre immunoglobuline für cd4-rezeptoren |
| US7037496B2 (en) | 1989-12-27 | 2006-05-02 | Centocor, Inc. | Chimeric immunoglobulin for CD4 receptors |
| SE9000333D0 (sv) * | 1990-01-31 | 1990-01-31 | Britta Wahren | Monoklonal antikropp |
| US5914109A (en) * | 1990-06-15 | 1999-06-22 | New York University | Heterohybridomas producing human monoclonal antibodies to HIV-1 |
| JP2989862B2 (ja) * | 1990-07-02 | 1999-12-13 | 財団法人化学及血清療法研究所 | モノクローナル抗体 |
| US5712373A (en) * | 1990-07-02 | 1998-01-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein |
| EP0550516A1 (de) * | 1990-09-28 | 1993-07-14 | Hospital For Joint Diseases | Verfahren zur hemmung der infektiosität des menschlichen immunschwäche virus |
| EP0554401A4 (en) * | 1990-10-26 | 1996-10-30 | New York Health Res Inst | Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120 |
| WO1992008983A1 (en) * | 1990-11-19 | 1992-05-29 | Queen's University At Kingston | Hiv marker/aids vaccine |
| WO1994004574A1 (en) * | 1991-08-22 | 1994-03-03 | Nissin Shokuhin Kabushiki Kaisha | Hiv immunotherapeutics |
| KR100251823B1 (ko) * | 1991-08-22 | 2000-04-15 | 안도 고끼 | 사람 면역 결핍 바이러스(hiv) 감염의 면역치료용 모노클로날 항체 |
| JPH0748276A (ja) * | 1992-03-26 | 1995-02-21 | Inmeru:Kk | Ｈｉｖ感染症予防ワクチンおよびその製造法 |
| FI944561A7 (fi) * | 1992-04-01 | 1994-09-30 | Merck & Co Inc | HIV:tä neutraloivia monoklonaalisia yhdistelmähumaanivasta-aineita HIV -infektion ehkäisemiseksi ja hoitamiseksi |
| GB9217124D0 (en) * | 1992-08-13 | 1992-09-23 | Antisoma Ltd | Medical treatment |
| US6114143A (en) * | 1993-03-11 | 2000-09-05 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-HIV monoclonal antibody |
| US5618922A (en) * | 1994-07-25 | 1997-04-08 | Nissin Shokuhin Kabushiki Kaisha | NM03 antibody materials and methods |
| AU6518698A (en) * | 1997-03-28 | 1998-10-22 | Seikagaku Corporation | Novel anti-hiv complexes and medicinal compositions |
| DE19809785C2 (de) * | 1998-03-08 | 2000-02-10 | Wolfgang Bergter | Radioimmunpharmakon zur Behandlung der HIV-1-Infektion |
| EP1006191A3 (de) | 1998-12-03 | 2002-02-06 | Canon Kabushiki Kaisha | Für Toluol-monooxygenase kodierende DNA, Verfahren zum Abbau von chlorierten aliphatischen Kohlenwasserstoffen und aromatischen Verbindungen, sowie Verfahren zur Entgiftung der Umwelt |
| BRPI0711586A2 (pt) * | 2006-05-15 | 2011-11-16 | Immunonomedics, Inc. | método para tratamento de infecção por hiv em um indivìduo, método para imagem latente detectar ou diagnosticar a infecção por hiv em um indivìduo, composição |
| CN107614515B (zh) | 2015-05-28 | 2022-03-22 | 免疫医疗公司 | 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5843926A (ja) * | 1981-09-08 | 1983-03-14 | Suntory Ltd | 選択性制癌剤 |
| FR2571968B1 (fr) * | 1984-10-18 | 1989-03-17 | Pasteur Institut | Virus purifie des lymphadenopathies et du syndrome d'immuno-depression acquise et antigenes d'enveloppe de ce virus, procede d'obtention de ce virus et de ces antigenes d'enveloppe de ce virus, applications de ce virus ou de ces antigenes a la preparation de compositions immunogenes ou pour le diagnostic des susdites affections. |
| JPS6147500A (ja) * | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| WO1986002383A1 (en) * | 1984-10-18 | 1986-04-24 | Institut Pasteur | Envelope antigens of lymphadenopathy associated virus and their applications |
| JP2702911B2 (ja) * | 1985-09-11 | 1998-01-26 | ユナイテツド・バイオメデイカル・インコ−ポレ−テツド | 合成ペプチド、並びにそれを用いたエイズおよびプリ・エイズの検出方法 |
| WO1987002775A1 (en) * | 1985-10-24 | 1987-05-07 | Southwest Foundation For Biomedical Research | Synthetic peptides and use for diagnosis and vaccination for aids and arc |
| NZ221440A (en) * | 1986-08-20 | 1991-11-26 | Genetic Systems Corp | Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections |
-
1988
- 1988-05-27 AT AT88906589T patent/ATE122237T1/de not_active IP Right Cessation
- 1988-05-27 DE DE3853779T patent/DE3853779T2/de not_active Expired - Fee Related
- 1988-05-27 JP JP63506387A patent/JP2520464B2/ja not_active Expired - Fee Related
- 1988-05-27 CA CA000567904A patent/CA1339857C/en not_active Expired - Fee Related
- 1988-05-27 EP EP88906589A patent/EP0366718B1/de not_active Expired - Lifetime
- 1988-05-27 WO PCT/US1988/001797 patent/WO1988009181A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1988009181A2 (en) | 1988-12-01 |
| EP0366718A1 (de) | 1990-05-09 |
| DE3853779D1 (de) | 1995-06-14 |
| EP0366718B1 (de) | 1995-05-10 |
| WO1988009181A3 (en) | 1989-02-09 |
| DE3853779T2 (de) | 1995-09-07 |
| CA1339857C (en) | 1998-05-05 |
| JPH03504556A (ja) | 1991-10-09 |
| JP2520464B2 (ja) | 1996-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3853779D1 (de) | Hiv-1 neutralisierende monoklonale antikörper. | |
| EP0724651A4 (de) | Synthetische humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch | |
| EP0675904A4 (de) | Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch. | |
| DE3850542T2 (de) | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. | |
| ES2006941A6 (es) | Un metodo de producir un peptido o una proteina relacionados con un epitope de virus asociado a linfoadenopatiasnvirus de leucemia de celulas t humanas (lavnhtlv-iii). | |
| AU563356B2 (en) | Conjugate of enzyme and antibody | |
| ES2010727A6 (es) | Metodo para producir lineas celulares que producen anticuerpos monoclonales reactivos frente a determinantes antigenicos de gp110 o de p25 de hiv. | |
| CA2082948A1 (en) | Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding | |
| IL118626A0 (en) | Anti HBV antibody | |
| ATE135743T1 (de) | Monoklonale menschliche antikörper gegen hiv-i | |
| ATE238420T1 (de) | Rekombinanter humanisierter antikörper gegen menschlichen immunschwächevirus | |
| DE69227500D1 (de) | In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper | |
| AU8010791A (en) | Hiv monoclonal antibody | |
| DE3854267D1 (de) | HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung. | |
| WO1993001820A3 (en) | Inhibition of non-cd4 mediated hiv infection | |
| WO1990013281A3 (en) | Method of suppressing hiv infection | |
| EP0323157A3 (de) | Antivirale Verbindungen und Methoden | |
| BG101175A (bg) | Тройна анти-нiv комбинация | |
| AU2190288A (en) | Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained | |
| DE3874606D1 (de) | Behandlung von viraler infektion. | |
| AU4832097A (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
| FR2646607B1 (fr) | Anticorps monoclonaux anti-b2 microglobuline | |
| AU660916B2 (en) | Beta-hydroxamate D-aspartic acid for treatment of viral infections and tumours | |
| DE69619123D1 (de) | Hämoregulatorische verbindungen | |
| ATE137801T1 (de) | Gegen hiv 1 gp48 spezifische antikörper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |